Krakow, Poland-based oncology specialist Ryvu Therapeutics (WSE: RVU) today announced that Vatnak Vat-Ho has joined the company as chief business officer.
In his position, Mr Vat-Ho will be responsible for a wide scope of corporate and business development activities at Ryvu including strategic positioning, partnering discussions, alliance management as well as investor interactions.
Mr Vat-Ho brings to Ryvu almost 20 years of professional experience spanning pharma, biotech, as well as capital markets expertise. He spent the first 10 years of his professional career in a variety of investment banks and global equity healthcare funds, including Broadfin Capital and BMO, later moving to the pharma and biotech industry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze